Table 3.

Association between miR-21 expression and clinicopathological features of LEAOD patients in the restenosis and non-restenosis groups

Feature	Restenosis group (n=79)				Non-restenosis group (n=327)
	Case	miR-21	t/χ2	P	Case	miR-21	t/χ2	P
Age (year)
<50	30	2.73 ± 0.84			132	1.15 ± 0.30
50–70	27	4.21 ± 0.63		<0.001	164	1.16 ± 0.32		0.104
>70	22	5.34 ± 0.84			31	1.03 ± 0.34
Fontaine staging
II	19	3.91 ± 1.24			155	1.17 ± 0.32
III	45	3.98 ± 1.39		0.982	162	1.12 ± 0.32		0.372
IV	15	3.96 ± 1.25			10	1.14 ± 0.11
Smoking
Yes	54	4.05 ± 1.34			215	1.13 ± 0.31
				0.382				0.178
No	25	3.77 ± 1.26			112	1.18 ± 0.33
Diabetes
Yes	50	4.20 ± 1.40			76	1.18 ± 0.27
				0.036				0.229
No	20	2.51 ± 0.86			257	1.13 ± 0.33
Hypertension
Yes	50	4.69 ± 0.93			118	1.18 ± 0.36
				<0.001				0.101
No	29	2.70 ± 0.84			209	1.12 ± 0.29
Coronary heart disease
Yes	15	3.87 ± 1.29			62	1.11 ± 0.42
				0.773				0.374
No	64	3.98 ± 1.33			265	1.15 ± 0.29
Hyperlipidaemia
Yes	14	3.57 ± 1.23		0.219	64	1.18 ± 0.31		0.260
No	65	4.05 ± 1.33			263	1.13 ± 0.32